Hyperbaric Oxygen Therapy in Retinal Arterial Occlusion: Epidemiology, Clinical Approach, and Visual Outcomes.
Journal
Case reports in ophthalmological medicine
ISSN: 2090-6722
Titre abrégé: Case Rep Ophthalmol Med
Pays: United States
ID NLM: 101581018
Informations de publication
Date de publication:
2019
2019
Historique:
received:
25
10
2019
revised:
23
11
2019
accepted:
28
11
2019
entrez:
25
2
2020
pubmed:
25
2
2020
medline:
25
2
2020
Statut:
epublish
Résumé
To evaluate the efficacy and safety of hyperbaric oxygen therapy (HBOT) in patients with acute retinal artery occlusion (RAO). Secondarily, to analyse the epidemiology and the clinical approach. Retrospective study of 13 patients submitted to HBOT between 2013 and 2018. The analysed parameters consisted of: systemic history, time between symptoms onset and treatment, initial approach, number of HBOT sessions, complications of HBOT and best corrected visual acuity-BCVA (of the total sample, central RAO-CRAO-group, and branch RAO-BRAO group). Arterial hypertension was the most prevalent systemic risk factor (53.8%). Initial therapies were 100% normobaric oxygen administration, topical and oral hypotensive medication, eye massage and aspirin. CRAO was observed in 69.2% and BRAO in 30.8% of the cases, with clinically significant visual improvement (a decrease in logMAR of 0.3) in 55.5% and 75%, respectively. Time between symptoms onset and treatment had a median of 9 hours. The median number of HBOT sessions was 7, without complications. HBOT provide BCVA improvement in patients with RAO, when it is performed in an early time after the symptom onset. It seems to be an effective and safe therapeutic option for a pathology that still remains without approved treatment.
Identifiants
pubmed: 32089924
doi: 10.1155/2019/9765938
pmc: PMC7012270
doi:
Types de publication
Case Reports
Langues
eng
Pagination
9765938Informations de copyright
Copyright © 2019 Ana Sofia Lopes et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Ophthalmologica. 1993;207(1):13-8
pubmed: 8278170
Circulation. 2003 Jun 17;107(23):2979-86
pubmed: 12814985
PLoS One. 2018 Aug 29;13(8):e0202154
pubmed: 30157206
Ann Eye Sci. 2018 Jun;3:
pubmed: 30198015
Diving Hyperb Med. 2011 Sep;41(3):135-8
pubmed: 21948498
Stroke. 2013 Jul;44(7):2064-89
pubmed: 23652265
Eye (Lond). 2013 Jun;27(6):688-97
pubmed: 23470793
Undersea Hyperb Med. 2008 Sep-Oct;35(5):333-87
pubmed: 19024664
Invest Ophthalmol Vis Sci. 2006 Mar;47(3):1236-40
pubmed: 16505064
Invest Ophthalmol Vis Sci. 2011 Sep 29;52(10):7514-22
pubmed: 21873680
Ophthalmology. 1996 Dec;103(12):2091-8
pubmed: 9003343
Diving Hyperb Med. 2017 Mar;47(1):24-32
pubmed: 28357821
Undersea Hyperb Med. 2009 Nov-Dec;36(6):401-5
pubmed: 20112531
Eur J Ophthalmol. 2001 Oct-Dec;11(4):345-50
pubmed: 11820305
BMJ Case Rep. 2017 May 12;2017:
pubmed: 28500127
Graefes Arch Clin Exp Ophthalmol. 2016 Nov;254(11):2209-2215
pubmed: 27480178
Undersea Hyperb Med. 2012 Sep-Oct;39(5):943-53
pubmed: 23045923
Neurol Clin. 2017 Feb;35(1):83-100
pubmed: 27886897
Exp Eye Res. 2004 Mar;78(3):723-36
pubmed: 15106952
Clin Ophthalmol. 2016 Dec 29;11:115-125
pubmed: 28096655
Am J Ophthalmol. 2005 Sep;140(3):376-91
pubmed: 16138997